The KEYLYNK-001 study evaluating Merck's Keytruda plus chemotherapy followed by maintenance with Lynparza meets the primary goal in epithelial ovarian cancer.
Merck & Co. Inc. (NYSE:MRK ) Citi's 2024 Global Healthcare Conference December 5, 2024 8:00 AM ET Company Participants Rob Davis - Chairman and CEO Eliav Barr - Senior VP, Head of Global Clinical Development and CMO Conference Call Participants Geoff Meacham - Citi Geoff Meacham Welcome to the morning session of the First Annual Citi Global Healthcare Conference. My name is Geoff Meacham.
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Merck & Co., Inc. (NYSE:MRK ) 7th Annual Evercore ISI HealthCONx Conference December 3, 2024 1:20 PM ET Company Participants Peter Dannenbaum - SVP, IR Eliav Barr - Chief Medical Officer Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Okay. Excellent.
MRK's study of PAH drug Winrevair in a more advanced form of the disease shows overwhelming efficacy.
On Monday, Merck & Co Inc MRK revealed topline results from the Phase 3 ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at high risk of mortality.
Merck said on Monday its drug, Winrevair, helped significantly reduce the risk of death in patients with a rare condition which causes high blood pressure in the lungs, months after it secured approval in the United States.
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In today's market, many investors are distracted by hype. But the real value lies in stocks that provide strong, consistent dividend yields without the noise. Instead of chasing the latest trends, focusing on high-yield dividend stocks that are undervalued is a smart strategy for building wealth over time. Two of my picks offer both deep value and high yields, making them standout opportunities for any dividend-focused portfolio.
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.
Merck & Co., Inc. (NYSE:MRK ) Jefferies London Healthcare Conference November 21, 2024 6:30 AM ET Corporate Participants Joe Romanelli - President, Human Health International Marjorie Green - SVP and Head of Oncology, Global Clinical Development, Merck Research Laboratories Conference Call Participants Akash Tewari - Jefferies Akash Tewari Good morning, everyone Day 3. We're at the end of it.
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist